Comerica Bank Trims Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Comerica Bank cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 36,270 shares of the medical equipment provider’s stock after selling 7,305 shares during the period. Comerica Bank’s holdings in Zimmer Biomet were worth $3,261,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZBH. M&T Bank Corp raised its stake in Zimmer Biomet by 15,705.6% during the 4th quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider’s stock valued at $321,158,000 after acquiring an additional 3,548,998 shares during the last quarter. Dodge & Cox raised its stake in Zimmer Biomet by 5.1% during the 3rd quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock valued at $2,286,793,000 after acquiring an additional 1,118,710 shares during the last quarter. AQR Capital Management LLC raised its stake in Zimmer Biomet by 276.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock valued at $118,627,000 after acquiring an additional 955,284 shares during the last quarter. Capital International Investors raised its stake in Zimmer Biomet by 11.5% during the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock valued at $743,749,000 after acquiring an additional 778,467 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC raised its stake in Zimmer Biomet by 3,633.7% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 464,250 shares of the medical equipment provider’s stock valued at $45,729,000 after acquiring an additional 451,816 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on ZBH shares. Citigroup reduced their price objective on Zimmer Biomet from $98.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday. Wall Street Zen cut Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Sunday, April 19th. UBS Group reiterated a “sell” rating and set a $89.00 target price on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Canaccord Genuity Group set a $83.00 target price on Zimmer Biomet in a research report on Wednesday. Finally, Evercore upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $94.00 to $120.00 in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $102.43.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $83.07 on Monday. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The business’s 50 day moving average is $92.53 and its two-hundred day moving average is $92.68. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.83 and a 12-month high of $108.29. The stock has a market capitalization of $16.08 billion, a price-to-earnings ratio of 21.58, a PEG ratio of 1.91 and a beta of 0.48.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were issued a $0.24 dividend. The ex-dividend date was Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.2%. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the sale, the senior vice president owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.28% of the stock is currently owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.